Advertisement

Cannabidiol as a potential medicine

  • Roger G. Pertwee
Part of the Milestones in Drug Therapy MDT book series (MDT)

Keywords

Anticonvulsant Activity Potential Medicine Commun Chem Pathol Suncus Murinus House Musk Shrew 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    ElSohly MA (2002) Chemical constituents of Cannabis. In: F Grotenhermen, E Russo (eds): Cannabis and cannabinoids. Pharmacology, toxicology and therapeutic potential. Haworth Press, New York, 27–36Google Scholar
  2. 2.
    McPartland JM, Russo EB (2001) Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Ther 1: 103–132CrossRefGoogle Scholar
  3. 3.
    Mechoulam R, Hanuš L (2002) Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 121: 35–43CrossRefPubMedGoogle Scholar
  4. 4.
    Mechoulam R, Gaoni Y (1967) Recent advances in the chemistry of hashish. Fortschr Chem Org Naturst 25: 175–213PubMedGoogle Scholar
  5. 5.
    Whittle BA, Guy GW, Robson P (2001) Prospects for new cannabis-based prescription medicines. J Cannabis Ther 1: 183–205CrossRefGoogle Scholar
  6. 6.
    Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR et al. RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161–202CrossRefPubMedGoogle Scholar
  7. 7.
    Pertwee RG (2004) Novel pharmacological targets for cannabinoids. Curr Neuropharmacol 2: 9–29CrossRefGoogle Scholar
  8. 8.
    Pertwee RG (2004) The pharmacology and therapeutic potential of cannabidiol. In: V Di Marzo (ed.): Cannabinoids. Kluwer Academic/Plenum Publishers, New York, 32–83Google Scholar
  9. 9.
    Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42: 11S–19SPubMedGoogle Scholar
  10. 10.
    Perez-Reyes M, Wingfield M (1974) Cannabidiol and electroencephalographic epileptic activity. J Am Med Ass 230: 1635CrossRefGoogle Scholar
  11. 11.
    Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21: 175–185PubMedGoogle Scholar
  12. 12.
    Carlini EA, Leite JR, Tannhauser M, Berardi AC (1973) Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol 25: 664–665PubMedGoogle Scholar
  13. 13.
    Carlini EA, Mechoulam R, Lander N (1975) Anticonvulsant activity of four oxygenated cannabidiol derivatives. Res Commun Chem Pathol Pharmacol 12: 1–15PubMedGoogle Scholar
  14. 14.
    Chiu P, Olsen DM, Borys HK, Karler R, Turkanis SA (1979) The influence of cannabidiol and Δ9-tetrahydrocannabinol on cobalt epilepsy in rats. Epilepsia 20: 365–375PubMedGoogle Scholar
  15. 15.
    Consroe P, Wolkin A (1977) Cannabidiol — antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther 201: 26–32PubMedGoogle Scholar
  16. 16.
    Consroe P, Martin P, Eisenstein D (1977) Anticonvulsant drug antagonism of Δ9-tetrahydrocannabinol induced seizures in rabbits. Res Commun Chem Pathol Pharmacol 16: 1–13PubMedGoogle Scholar
  17. 17.
    Consroe P, Martin A, Singh V (1981) Antiepileptic potential of cannabidiol analogs. J Clin Pharmacol 21: 428S–436SPubMedGoogle Scholar
  18. 18.
    Consroe P, Benedito MAC, Leite JR, Carlini EA, Mechoulam R (1982) Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 83: 293–298CrossRefPubMedGoogle Scholar
  19. 19.
    Izquierdo I, Tannhauser M (1973) The effect of cannabidiol on maximal electroshock seizures in rats. J Pharm Pharmacol 25: 916–917PubMedGoogle Scholar
  20. 20.
    Karler R, Cely W, Turkanis SA (1973) The anticonvulsant activity of cannabidiol and cannabinol. Life Sci 13: 1527–1531CrossRefPubMedGoogle Scholar
  21. 21.
    Karler R, Cely W, Turkanis SA (1974) A study of the relative anticonvulsant and toxic activities of Δ9-tetrahydrocannabinol and its congeners. Res Commun Chem Pathol Pharmacol 7: 353–358PubMedGoogle Scholar
  22. 22.
    Karler R, Cely W, Turkanis SA (1974) A study of the development of tolerance to an anticonvulsant effect of Δ9-tetrahydrocannabinol and cannabidiol. Res Commun Chem Pathol Pharmacol 9: 23–39PubMedGoogle Scholar
  23. 23.
    Karler R, Cely W, Turkanis SA (1974) Anticonvulsant properties of Δ9-tetrahydrocannabinol and other cannabinoids. Life Sci 15: 931–947CrossRefPubMedGoogle Scholar
  24. 24.
    Karler R, Turkanis SA (1980) Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice. Br J Pharmacol 68: 479–484PubMedGoogle Scholar
  25. 25.
    Karler R, Borys HK, Turkanis SA (1982) Influence of 22-day treatment on the anticonvulsant properties of cannabinoids. Naunyn-Schmiedeberg’s Arch Pharmacol 320: 105–109CrossRefGoogle Scholar
  26. 26.
    Karler R, Murphy V, Calder LD, Turkanis SA (1989) Pentylenetetrazol kindling in mice. Neuropharmacology 28: 775–780CrossRefPubMedGoogle Scholar
  27. 27.
    Leite JR, Carlini EA, Lander N, Mechoulam R (1982) Anticonvulsant effects of the (−) and (+) isomers of cannabidiol and their dimethylheptyl homologs. Pharmacology 24: 141–146PubMedGoogle Scholar
  28. 28.
    Lindamood C, Colasanti BK (1980) Effects of Δ9-tetrahydrocannabinol and cannabidiol on sodium-dependent high affinity choline uptake in the rat hippocampus. J Pharmacol Exp Ther 213: 216–221PubMedGoogle Scholar
  29. 29.
    Martin BR, Harris LS, Dewey WL (1984) Pharmacological activity of delta-9-THC metabolites and analogs of CBD, delta-8-THC and delta-9-THC. In: S Agurell, WL Dewey and RE Willette (eds): The Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects. Academic Press, Orlando, FL, 523–544Google Scholar
  30. 30.
    Turkanis SA, Cely W, Olsen DM, Karler R (1974) Anticonvulsant properties of cannabidiol. Res Commun Chem Pathol Pharmacol 8: 231–246PubMedGoogle Scholar
  31. 31.
    Turkanis SA, Smiley KA, Borys HK, Olsen DM, Karler R (1979) An electrophysiological analysis of the anticonvulsant action of cannabidiol on limbic seizures in conscious rats. Epilepsia 20: 351–363PubMedGoogle Scholar
  32. 32.
    Turkanis SA, Karler R (1981) Electrophysiologic properties of the cannabinoids. J Clin Pharmacol 21: 449S–463SPubMedGoogle Scholar
  33. 33.
    Turkanis SA, Karler R (1981) Excitatory and depressant effects of Δ9-tetrahydrocannabinol and cannabidiol on cortical evoked responses in the conscious rat. Psychopharmacology 75: 294–298CrossRefPubMedGoogle Scholar
  34. 34.
    Usami N, Okuda T, Yoshida H, Kimura T, Watanabe K, Yoshimura H, Yamamoto I (1999) Synthesis and pharmacological evaluation in mice of halogenated cannabidiol derivatives. Chem Pharm Bull 47: 1641–1645PubMedGoogle Scholar
  35. 35.
    Wallace MJ, Wiley JL, Martin BR, DeLorenzo RJ (2001) Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol 428: 51–57CrossRefPubMedGoogle Scholar
  36. 36.
    Chesher GB, Jackson DM (1974) Anticonvulsant effects of cannabinoids in mice: drug interactions within cannabinoids and cannabinoid interactions with phenytoin. Psychopharmacology 37: 255–264CrossRefGoogle Scholar
  37. 37.
    Chesher GB, Jackson DM, Malor RM (1975) Interaction of Δ9-tetrahydrocannabinol and cannabidiol with phenobarbitone in protecting mice from electrically induced convulsions. J Pharm Pharmacol 27: 608–609PubMedGoogle Scholar
  38. 38.
    Karler R, Turkanis SA (1979) Cannabis and epilepsy. In: GG Nahas and WDM Paton (eds): Marihuana: Biological Effects. Pergamon Press, Oxford, 619–641Google Scholar
  39. 39.
    Karler R, Turkanis SA (1981) The cannabinoids as potential antiepileptics. J Clin Pharmacol (suppl) 21: 437S–448SPubMedGoogle Scholar
  40. 40.
    Karler R, Cely W, Turkanis SA (1974) Anticonvulsant activity of Δ9-tetrahydrocannabinol and its 11-hydroxy and 8α, 11-dihydroxy metabolites in the frog. Res Commun Chem Pathol Pharmacol 9: 441–452PubMedGoogle Scholar
  41. 41.
    Banerjee SP, Snyder SH, Mechoulam R (1975) Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. J Pharmacol Exp Ther 194: 74–81PubMedGoogle Scholar
  42. 42.
    Bisogno T, Hanuš L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845–852CrossRefPubMedGoogle Scholar
  43. 43.
    Bloom AS (1984) Effects of cannabinoids on neurotransmitter receptors in the brain. In: S Agurell, WL Dewey and RE Willette (eds): The Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects. Academic Press, Orlando, FL, 575–589Google Scholar
  44. 44.
    Bloom AS, Hillard CJ (1985) Cannabinoids, neurotransmitter receptors and brain membranes. In: DJ Harvey (ed.): Marihuana ‘84. IRL Press, Oxford, 217–231Google Scholar
  45. 45.
    Harris RA, Stokes JA (1982) Cannabinoids inhibit calcium uptake by brain synaptosomes. J Neurosci 2: 443–447PubMedGoogle Scholar
  46. 46.
    Hershkowitz M, Goldman R, Raz A (1977) Effects of cannabinoids on neurotransmitter uptake, ATPase activity and morphology of mouse brain synaptosomes. Biochem Pharmacol 26: 1327–1331CrossRefGoogle Scholar
  47. 47.
    Pertwee RG, Ross RA, Craib SJ, Thomas A (2002) (™)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 456: 99–106CrossRefPubMedGoogle Scholar
  48. 48.
    Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998) Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63: PL1–PL6CrossRefPubMedGoogle Scholar
  49. 49.
    Poddar MK, Dewey WL (1980) Effects of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes. J Pharmacol Exp Ther 214: 63–67PubMedGoogle Scholar
  50. 50.
    Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278: 989–999PubMedGoogle Scholar
  51. 51.
    Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH (1998) Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 285: 285–292PubMedGoogle Scholar
  52. 52.
    Consroe P, Martin A, Mechoulam R (1985) Anticonvulsant effects of cannabidiol stereoisomers and analogs in rats. In: DJ Harvey (ed.): Marihuana ‘84. IRL Press, Oxford, 705–712Google Scholar
  53. 53.
    Turkanis SA, Karler R (1975) Influence of anticonvulsant cannabinoids on post tetanic potentiation of isolated Bullfrog ganglia. Life Sci 17: 569–578CrossRefPubMedGoogle Scholar
  54. 54.
    Sandyk R, Consroe P, Stern L, Snider SR, Bliklen D (1988) Preliminary trial of cannabidiol in Huntington’s Disease. In: G Chesher, P Consroe and R Musty (eds): Marihuana: An International Research Report. Australian Gov. Publ. Service, Canberra, 157–162Google Scholar
  55. 55.
    Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K (1991) Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav 40: 701–708CrossRefPubMedGoogle Scholar
  56. 56.
    Consroe P, Sandyk R, Snider SR (1986) Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 30: 277–282PubMedGoogle Scholar
  57. 57.
    Sandyk R, Snider SR, Consroe P, Elias SM (1986) Cannabidiol in dystonic movement disorders. Psychiat Res 18: 291CrossRefGoogle Scholar
  58. 58.
    Richter A, Löscher W (2002) Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia. Eur J Pharmacol 454: 145–151CrossRefPubMedGoogle Scholar
  59. 59.
    Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS (1993) Effect of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7: 82–88Google Scholar
  60. 60.
    Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM (2000) Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav 66: 175–181CrossRefPubMedGoogle Scholar
  61. 61.
    Zuardi AW, Guimaraes FS, Moreira AC (1993) Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Brazilian J Med Biol Res 26: 213–217Google Scholar
  62. 62.
    Crippa JAD, Zuardi AW, Garrido GEJ, Wichert-Ana L, Guarnieri R, Ferrari L, Azevedo-Marques PM, Hallak JEC, McGuire PK, Busatto GF (2004) Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29: 417–426CrossRefPubMedGoogle Scholar
  63. 63.
    Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA (1974) Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man. Eur J Pharmacol 28: 172–177CrossRefPubMedGoogle Scholar
  64. 64.
    Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by Δ9-THC in normal subjects. Psychopharmacology 76: 245–250CrossRefGoogle Scholar
  65. 65.
    Onaivi ES, Green MR, Martin BR (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253: 1002–1009PubMedGoogle Scholar
  66. 66.
    Guimaraes FS, Chiaretti TM, Graeff FG, Zuardi AW (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 100: 558–559PubMedGoogle Scholar
  67. 67.
    Zuardi AW, Rodrigues JA, Cunha JM (1991) Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology 104: 260–264PubMedGoogle Scholar
  68. 68.
    Mechoulam R, Panikashvili D, Shohami E (2002) Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 8: 58–61CrossRefPubMedGoogle Scholar
  69. 69.
    van der Stelt M, Veldhuis WB, Maccarrone M, Bär PR, Nicolay K, Veldink GA, Di Marzo V, Vliegenthart JFG (2002) Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 26: 317–346CrossRefPubMedGoogle Scholar
  70. 70.
    Fowler CJ (2003) Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents: non-psychoactive cannabinoids, ‘entourage’ compounds and inhibitors of N-acyl ethanolarnine breakdown as therapeutic strategies to avoid pyschotropic effects. Brain Res Rev 41: 26–43CrossRefPubMedGoogle Scholar
  71. 71.
    Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C (2002) Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 80:448–456CrossRefPubMedGoogle Scholar
  72. 72.
    El-Remessy AB, Khalil IE, Matragoon S, Abou-Mohamed G, Tsai N-J, Roon P, Caldwell RB, Caldwell RW, Green K, Liou GI (2003) Neuroprotective effect of (™)Δ9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am J Pathol 163: 1997–2008PubMedGoogle Scholar
  73. 73.
    Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (™)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95: 8268–8273CrossRefPubMedGoogle Scholar
  74. 74.
    Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J (2000) Neuroprotective antioxidants from marijuana. In: Reactive oxygen species: from radiation to molecular biology. Annals NY Acad Sci 899: 274–282Google Scholar
  75. 75.
    Drysdale AJ, Pertwee RG, Platt B (2004) Modulation of calcium homeostasis by cannabidiol in primary hippocampal culture. Proc Br Pharmacol Soc at http://www.pa2online.org/VollIssue4abst052P.htmlGoogle Scholar
  76. 76.
    Braida D, Pegorini S, Arcidiacono MV, Consalez GG, Croci L, Sala M (2003) Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils. Neurosci Lett 346: 61–64CrossRefPubMedGoogle Scholar
  77. 77.
    Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97: 9561–9566CrossRefPubMedGoogle Scholar
  78. 78.
    Pertwee RG (2000) Neuropharmacology and therapeutic potential of cannabinoids. Addiction Biol 5: 37–46CrossRefGoogle Scholar
  79. 79.
    Chen Y, Buck J (2000) Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J Pharmacol Exp Ther 293: 807–812PubMedGoogle Scholar
  80. 80.
    Lodzki M, Godin B, Rakou L, Mechoulam R, Gallily R, Touitou E (2003) Cannabidiol — transdermal delivery and anti-inflammatory effect in a murine model. J Control Release 93: 377–387CrossRefPubMedGoogle Scholar
  81. 81.
    Formukong EA, Evans AT, Evans FJ, Garland LG (1991) Inhibition of A23187-induced release of leukotriene B4 in mouse whole blood ex vivo and human polymorphonuclear cells in vitro by the cannabinoid analgesic cannabidiol. Phytotherapy Res 5: 258–261Google Scholar
  82. 82.
    Costa B, Colleoni M, Conti S, Parolaro D, Franke C, Trovato AE, Giagnoni G (2004) Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn-Schmiedeberg’s Arch Pharmacol 369: 294–299CrossRefGoogle Scholar
  83. 83.
    Burstein S, Hunter SA, Ozman K, Renzulli L (1985) In vitro models of cannabinoid-induced pschoactivity. In: DJ Harvey (ed.): Marihuana ‘84. IRL Press, Oxford, 399–406Google Scholar
  84. 84.
    Formukong EA, Evans AT, Evans FJ (1988) Analgesic and antiinflammatory activity of constituents of Cannabis sativa L. Inflammation 12: 361–371CrossRefPubMedGoogle Scholar
  85. 85.
    Sofia RD, Vassar HB, Knobloch LC (1975) Comparative analgesic activity of various naturally occurring cannabinoids in mice and rats. Psychopharmacologia 40: 285–295CrossRefPubMedGoogle Scholar
  86. 86.
    Evans AT, Formukong EA, Evans FJ (1987) Actions of cannabis constituents on enzymes of arachidonate metabolism: anti-inflammatory potential. Biochem Pharmacol 36: 2035–2037CrossRefPubMedGoogle Scholar
  87. 87.
    Watzl B, Scuderi P, Watson RR (1991) Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-l-alpha in vitro. Int J Immunopharmacol 13: 1091–1097PubMedGoogle Scholar
  88. 88.
    Watzl B, Scuderi P, Watson RR (1991) Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. In: H Friedman, S Specter, TW Klein (eds): Drugs of Abuse, Immunity, and Immunodeficiency. Plenum Press, New York, Adv Exp Med Biol 288: 63–70Google Scholar
  89. 89.
    Burstein S, Levin E, Varanelli C (1973) Prostaglandins and cannabis — II. Biochem Pharmacol 22: 2905–2910CrossRefPubMedGoogle Scholar
  90. 90.
    White HL, Tansik RL (1980) Effects of Δ9-tetrahydrocannabinol and cannabidiol on phospholipase and other enzymes regulating arachidonate metabolism. Prostaglandins and Medicine 4: 409–417CrossRefPubMedGoogle Scholar
  91. 91.
    Spronck HJW, Luteijn JM, Salemink CA, Nugteren DH (1978) Inhibition of prostaglandin biosynthesis by derivatives of olivetol formed under pyrolysis of cannabidiol. Biochem Pharmacol 27: 607–608CrossRefPubMedGoogle Scholar
  92. 92.
    Burstein S, Hunter SA, Ozman K (1983) Prostaglandins and Cannabis XII. The effect of cannabinoid structure on the synthesis of prostaglandins by human lung fibroblasts. Mol Pharmacol 23: 121–126PubMedGoogle Scholar
  93. 93.
    Burstein S, Hunter SA (1978) Prostaglandins and cannabis — VI. Release of arachidonic acid from HeLa cells by Δ1-tetrahydrocannabinol and other cannabinoids. Biochem Pharmacol 27: 1275–1280CrossRefPubMedGoogle Scholar
  94. 94.
    Evans AT, Formukong E, Evans FJ (1987) Activation of phospholipase A2 by cannabinoids: lack of correlation with CNS effects. FEBS Lett 211: 119–122CrossRefPubMedGoogle Scholar
  95. 95.
    Srivastava MD, Srivastava BIS, Brouhard B (1998) Δ9 Tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacol 40: 179–185CrossRefGoogle Scholar
  96. 96.
    Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23: 1398–1405PubMedGoogle Scholar
  97. 97.
    Parker LA, Mechoulam R, Schlievert C (2002) Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 13: 567–570CrossRefPubMedGoogle Scholar
  98. 98.
    Parker LA, Mechoulam R (2003) Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. Integr Physiol Behav Sci 38: 134–146Google Scholar
  99. 99.
    Limebeer CL, Parker LA (1999) Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned disgust reactions produced by cyclophosphamide: a rat model of nausea. Neuroreport 10: 3769–3772PubMedGoogle Scholar
  100. 100.
    Limebeer CL, Parker LA (2000) Ondansetron interferes with the establishment and the expression of conditioned disgust reactions: a rat model of nausea. J Exp Psychol Anim Behav Process 26: 371–384CrossRefPubMedGoogle Scholar
  101. 101.
    Parker LA, Kwiatkowska M, Burton P, Mechoulam R (2004) Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology 171: 156–161CrossRefPubMedGoogle Scholar
  102. 102.
    Kwiatkowska M, Parker LA, Burton P, Mechoulam R (2004) A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology 174: 254–259PubMedGoogle Scholar
  103. 103.
    Darmani NA (2002) The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachi-donoylglycerol) are blocked by Δ9-tetrahydrocannabinol and other cannnabinoids. J Pharmacol Exp Ther 300: 34–42CrossRefPubMedGoogle Scholar
  104. 104.
    Colasanti BK, Brown RE, Craig CR (1984) Ocular hypotension, ocular toxicity and neurotoxicity in response to marihuana extract and cannabidiol. Gen Pharmacol 15: 479–484PubMedGoogle Scholar
  105. 105.
    Monti JM (1977) Hypnotic-like effects of cannabidiol in the rat. Psychopharmacology 55: 263–265CrossRefPubMedGoogle Scholar
  106. 106.
    Sofia RD, Knobloch LC (1976) Comparative effects of various naturally occurring cannabinoids on food, sucrose and water consumption by rats. Pharmacol Biochem Behav 4: 591–599CrossRefPubMedGoogle Scholar
  107. 107.
    Silveira Filho NG, Tufik S (1981) Comparative effects between cannabidiol and diazepam on neophobia, food intake and conflict behavior. Res Commun Psychol Psychiat Behav 6: 251–266Google Scholar
  108. 108.
    Murison G, Chubb CBH, Maeda S, Gemmell MA, Huberman E (1987) Cannabinoids induce incomplete maturation of cultured human leukemia cells. Proc Natl Acad Sci USA 84: 5414–5418PubMedGoogle Scholar
  109. 109.
    Han DS, Jung KH, Jung WY, Oh IK, Kang KU, Baek SH (2000) Synthesis and cytotoxic effects of deoxy-tomentellin. Arch Pharmacol Res 23: 121–127Google Scholar
  110. 110.
    Jacobsson SOP, Rongård E, Stridh M, Tiger G, Fowler CJ (2000) Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol 60: 1807–1813CrossRefPubMedGoogle Scholar
  111. 111.
    Gallily R, Even-Chen T, Katzavian G, Lehmann D, Dagan A, Mechoulam R (2003) γ-Irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma 44: 1767–1773CrossRefPubMedGoogle Scholar
  112. 112.
    Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D (2004) Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308: 838–845CrossRefPubMedGoogle Scholar
  113. 113.
    Kogan NM, Rabinowitz R, Levi P, Gibson D, Sandor P, Schlesinger M, Mechoulam R (2004) Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J Med Chem 47: 3800–3806CrossRefPubMedGoogle Scholar
  114. 114.
    Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on β-amyloid-induced toxicity in PC12 cells. J Neurochem 89: 134–141PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2005

Authors and Affiliations

  • Roger G. Pertwee
    • 1
  1. 1.School of Medical Sciences, Institute of Medical SciencesUniversity of Aberdeen, ForesterhillAberdeenScotland UK

Personalised recommendations